Trasylol

Ready to Help Whenever You Need Us

We know who to talk to, where to find answers, and what steps you need to take. Let us put our 30 years of experience to work for you.

Anti-Bleeding Drug Trasylol Linked to Increased Risk of Death, Kidney Failure, Congestive Heart Failure, and Stroke

February 21, 2008—The results of two studies published in the New England Journal of Medicine show an increased risk of death for heart patients given the anti-bleeding drug Trasylol (aprotinin injection). Trasylol, which has been on the market for 14 years, was used during cardiac bypass surgery to reduce blood loss and decrease the need for blood transfusions. Trasylol manufacturer, Bayer Pharmaceuticals, has come under scrutiny by the U.S. Food and Drug Administration (FDA) for not sharing data on the risks associated with Trasylol use.

The release of these two Trasylol studies comes on the heels of a "60 Minutes" interview with medical researcher Dr. Dennis Mangano, which aired Sunday, February 17, 2008. Dr. Mangano conducted the largest ever Trasylol study, which included 5,065 patients in 17 countries. The study, published in the New England Journal of Medicine in January 2006, revealed that patients treated with Trasylol have twice the rate of kidney failure and an increased risk of heart attacks, heart failure, strokes and encephalopathy.

If you or your loved one has suffered a Trasylol injury, contact us today. Submit the form to the right and we’ll let you know if you have a case and if we can represent you.